Edible Plant Vaccines: A Step Towards Revolution in the Field of
Immunology
Muneeba Bibi
Qureshi*†, Sara Arif† and Sobia Sanawar Rathore†
Department of
bioinformatics and biotechnology, International Islamic University, Sector
H-10, 44000 Islamabad, Pakistan
*For correspondence: muneeba.qureshi1@gmail.com
†Contributed equally to this work and
are co-authors
Received 14 March 2023;
Accepted 28 March 2023; Published 13 April 2023
Abstract
Plants that express vaccine antigens are
a viable strategy since recent advancements in immunology and molecular biology
have resulted in the creation of novel vaccination tactics. There are a variety
of systems to deliver vaccines but transgenic plants provide alternative means
for the manufacture and distribution of vaccinations. It is less expensive,
takes less time to transport, needs less refrigeration, and for a long time, it
may be kept at room temperature to make in-plant edible vaccines. As a result,
vaccines made from plants could be more broadly accessible in underdeveloped
countries. Besides the advantages, there are a number of challenges in creating
an edible vaccine, including dose, antigen choice, public image, the shelf life
of the plants used as vaccines, and differentiation between "vaccine"
fruit and regular fruit to prevent improper vaccination. Edible plant vaccines
can increase both mucosal and systemic immunity. The best plants for making
edible vaccines include tobacco, potato, tomato, and banana. Up to this point,
plant-based vaccinations have been created to protect against illnesses
including Cholera, Hepatitis, Malaria, Newcastle disease, Measles and the
Rabies virus. Animal studies have shown that antigenic proteins produced from
plants can delay the development of illness, and human therapeutic trials have
demonstrated their safety and efficacy. There are currently very few approved
vaccines made from edible plants that are being tested on both humans and
animals. This paper examines recent developments, manufacturing techniques, and
applications for edible vaccines. © 2023 Friends Science Publishers
Keywords: Edible
vaccines; Antigen; Tobacco; Hepatitis; Mucosal immunity; Plants
Immunization is a procedure that
fortifies the body so that it can defend itself from any upcoming pathogenic
invasion. A sort of immunization, vaccination is the process of giving out and
delivering vaccines (Malik et al. 2011). Vaccines are intended to strengthen the immune system
without actually transmitting disease. Conventional vaccinations contain
disease-causing organisms that have been killed or diminished, making them not
entirely safe. Their downsides include antigenic diversity among species, a low
level of immunogenicity, a propensity for gene transfer in wild-type strains
and a high probability of turning virulent again (Mishra et al. 2008; Chan and Daniell 2015). A
large poliomyelitis outbreak was started in northern Nigeria in 2005 by a type 2
circulating vaccine-derived poliovirus (cVDPV2), which spread to the rest of
Africa in 2006 and is still active today. In order to improve current
immunizations, new strategies are required (Famulare and Hu 2015).
Previous research has demonstrated that
transgenic plants may be used to generate and transport vaccinations. Antigens
originating from numerous diseases can be produced in plants in high quantities
and in their natural forms (Streatfield
et al. 2001; Pyrski et al. 2019). Edible vaccines
primarily include antigens and do not contain whole pathogen-forming genes.
Since plants may produce more than one transgene, they can provide several
antigens for recurrent inoculations. Edible vaccinations for illnesses such as
cholera, foot and mouse disease, measles, hepatitis B and C6 are now being
developed. The first study of the edible vaccine (a surface protein from Streptococcus
found in tobacco) was reported as a patent application in 1990. under the
worldwide patent cooperation treaty (Mishra
et al. 2008). Several present
restrictions are eliminated by plants with subunit vaccinations. Plant-based
vaccinations are affordable since they simply require sunlight, water, and
nutrients to grow and thrive. The likelihood of contamination is reduced with
plant-based vaccines, which also offer oral doses and a thermally stable
environment, removing the potential for injection-related problems (Walmsley
and Arntzen 2000; Stander et al. 2022). Orally administered edible plant vaccines stimulate
the immune system and offer disease protection. Future vaccination delivery
methods may undergo a revolution thanks to recombinant vaccines. Vaccine
production will be more affordable through vaccinations made from plant tissues
and the consumption of plant-based meals. Consumers can eat 1000 times more
antigens than would be available by injection for the same cost. Scientists are
also looking at utilizing maize grain as a delivery technique for consumable
immunizations. These include vaccinations for the swine transmissible
gastroenteritis virus and certain strains of Escherichia coli (ETEC)
(TGEV) (Haq et al. 1995; Streatfield
et al. 2001).
Mucosal and systemic immunity are
both boosted when vaccinations consumed come into contact with the lining of
the digestive tract. A first line of defense against diseases of the mucous
membrane would be provided by their combined effect. The M cells in the ileum
(Payer's patches) and the lymphoid tissue connected to the gut both take up the
antigens generated in the intestines (GALT) (Rossi et al. 2015). The vaccination antigen is preserved from deterioration
by plants and also acts as a delivery mechanism for the vaccination into the
git. This technique allows the vaccine antigen to successfully enter the
mucosal immune system (Hefferon 2013).
Initial
advancements in plant-based vaccines
By effectively synthesizing SpaA (Streptococcus
mutans surface protein antigen a) in tobacco plants, Curtiss and Cardineau
demonstrated the first instance of plant vaccine expression in 1990. When
transgenic tobacco tissues were provided in place of the pathogen, antibodies
were shown to be physiologically active against S. mutans. Eventually, as a result of the use of this technology,
plants generated many antigens, including the hepatitis antigen in tobacco and
lettuce, the rabies antigen in tomato, the cholera antigen in tobacco and
potatoes, and the human CMV antigen in tobacco. In 1993, it was discovered that
the cowpea mosaic virus surface included an FMDV epitope (CPMV). The
utilization of chimeric plant viruses as proteins that transmit carcinogens was
proven in 1994 by rabbits' immune reactions to pure chimeric (CPMV) particles
expressing epitopes from the human rhinovirus 14 (HRV-14) and HIV-1 (Walmsley
and Arntzen 2000; Pyrski et al. 2019). Scientists asked
participants to consume anti-diarrheal transgenic potatoes in 1997, marking the
first of edible vaccination testing on people. All participants produced
antigens in their systems after eating potatoes, precisely as they do after
standard anti-diarrheal immunization, with no negative effects. Volunteers are
also testing a Hepatitis B antigen expressed in raw potatoes. After witnessing
such a positive outcome from this trial, the NIAID encouraged the researchers
to use this approach to develop vaccines for additional illnesses (Doshi et
al. 2013).
The use of these vaccinations in both
humans and plants is the focus of the current investigation on the synthesis of
plant vaccines. Despite the fact that there aren't any plant-based vaccinations
on the market right now, some of them have regulatory approval. They include a
secretory antibody vaccine that received EU authorization, a chicken Newcastle
disease vaccine that received USDA approval and a tobacco-based hepatitis B
virus vaccine that received Cuban authorization (Tacket
and Mason 1999). Many plant-based vaccines are now undergoing human
trials, including one based on potatoes that defend against the rabies virus
and one that defends against the hepatitis B virus. Data on the dose, ideal
administration method, response type, strength, and duration have been
generated for illnesses such as Vibrio cholera, HIV, Pseudomonas
aeruginosa, murine hepatitis virus, and foot-and-mouth disease
virus. Hence, the introduction of plant-consumable vaccines is anticipated
within next several years. Increasing transgene expression in transgenic plants
is one of the current main objectives. In plants, a number of reported codes or
sequences may have resulted in improper processing or premature genotoxic
eradication. Synthetic genes were produced by removing these directives. As a
result, antigen accumulation increased 314 times in leaves and tubers. The
results of the research involving the feeding of mice were eliminated. Antigen
accumulation increased 3–14 times in leaves and tubers as a result. Studies on
mouse feeding provided evidence for the findings (Walmsley and Arntzen 2000).
Selection of
plants for the manufacture of an edible vaccine
Banana: The vaccination
is given in the form of banana trees and tomato plants that were genetically
engineered at the Boyce Thompson Institute for Plant Research. Bananas are
viewed as a promising source of vaccine manufacture since they are widely
available, can be eaten raw, and are popular with children in several emerging
global areas (Langridge 2000). Banana is also regarded as the greatest host for
vaccine manufacturing since it provides benefits such as digestibility and
palatability to newborns. They are readily available all year round in any area
of the world where strong antibodies are needed to vaccinate a sizable section
of the populace. The edible banana is ideal for quality control since it
doesn't have seeds and develops from a tree's stem, making it challenging to
detect transgenes (Kumar et al. 2005). The disadvantage
of using bananas is that the fruit degrades quickly after reaching maturity
whereas the banana plant takes several years to mature. Agrobacterium
transformation, particle bombardment and electroporation are just a few
techniques that may be used to genetically modify bananas.
Tomato: Scientists at
Loma Linda University conducted numerous studies and came to the conclusion
that antigens may be generated by tomato plants. Tomato cultivation or growth
is done quickly and in big quantities, however it is not that rapid (Langridge
2000). The HBsAg factor-containing tomato that transforms and regenerates has
been considered (Cortina and
Culiáñez-Macià 2004; Wang and Li 2008). Bock and his colleagues have reported on a tomato plastid
transformation in which plastid transgene in tomato plants may attain a
noteworthy amount of protein. Their research led to the discovery that an edible
vaccine may be created by transforming tomato plastids. The only distinct
transplastomic plants identified as viable and capable of passing on transgenes
to subsequent generations are the tomato plants described by Bock and
colleagues (Maliga 2001).
Potatoes:
Because they don't require refrigeration for long-term
storage, potatoes are regarded as being suitable for the creation of vaccines.
Another seen was the consumption of uncooked potatoes in South America. The
protein in potatoes denatures when heated, yet surprisingly, it was discovered
that the antigen in the potatoes was not fully destroyed (Langridge 2000).
Tobacco: Charles
Arntzen's cluster at Lone Star State A & M in the United States was the
first to discover the tobacco plant's expression of the hepatitis B surface
antigen (Tregoning et al. 2004). The buildup of recombinant SARS CoV prickle protein
in the cytosol and chloroplasts of tobacco plants is one of the various
recombinant virus vaccines produced recently in transgenic plants (Li et al.
2006) and T.B. antigen overexpression in tobacco leaves (Dorokhov et al. 2007).
Additional
plants used in edible vaccines
Lettuce, rice, wheat, soybeans, and
corn are also used to make edible vaccinations. Vaccines against
enterotoxigenic strains of Escherichia (ETEC) and swine-transmissible
gastroenteritis virus have been generated using corn grains (TGEV) (Streatfield et al. 2001). Arabidopsis
and rice are likewise genetically altered, but they cannot pass genes on to
future generations (Maliga 2001). Transgenic tobacco plants, tobacco cells,
lettuce and ligneous plant, carrot, and potato are the primary sources of
hepatitis B antigen production (HBsAg) (Kumar et al. 2005; Karaman et al. 2006).
Numerous different plants that express VP1 include cress, alfalfa, potato, and
a variety of others (Kim et al. 2009). Because alfalfa is known to be more effective at encouraging the
expression of the FMDV VP1 protein. Transgenic apples have also expressed the
HBV expansion surface antigen PRS-S1S2S quality (Lou et al. 2005).
The following are the plant expression
system strategies:
Agrobacterium-mediated transformation: There are other techniques to
modify plants, but Agrobacterium-mediated transformation is best for
developing edible vaccines. The host becomes infected after Agrobacterium
inserts a DNA fragment (TDNA) into its genome. By employing this technique, we
insert our target gene into the plant genome (Walmsley and Arntzen 2000). plant pathogen A. tumefaciens
successfully introduces DNA into the host plant, where it fuses with several
chromosomal sites in the nucleus. In certain Agrobacterium strains, the
virulence genes that cause plant tumor development have been eliminated, but
the genes that encourage efficient gene transfer have been maintained. The target
gene (antigen) is supplied and after integrating with the plant's nucleus, it is
produced and normally is handed down through generations (Fig. 1).
Biolistic method: Several
important plant species, such as soybean and the bulk of cereal grains, cannot
be transformed by Agrobacterium. For gene transfer in such plants, a
biolistic technique is used. In comparison to Agrobacterium
transformation, the biolistic approach has certain advantages since it causes
the incorporation of foreign genes in large copy numbers, which improves
expression. The genome of the chloroplast is expanded using transgenes. High
chloroplast genome copy number increases recombinant protein expression in
plant cells. Plant phenotype is less impacted by nuclear-mediated expression of
recombinant proteins than chloroplast-mediated expression. Chloroplast
transformation has been utilized to express 25 different foreign genes, despite
the fact that this is a relatively uncommon process (Sharma and Sood 2011).
Electroporation: This process involves briefly exposing plant cells to a
high-voltage electrical pulse in order to introduce DNA into the cells. It
results in momentary plasma membrane gaps. DNA must get through the strong cell
wall to enter the cell cytoplasm. To do this, we first weaken the cell membrane
with moderate enzymatic treatment and then enable DNA to slip through (Singh 2002).
Transient expression: According to
this method of expression, a plant virus that contains the vaccine gene infects
the plant systemically (Mason et al.
2002). For the plant viral genome to create a significant number of copies of
recombinant proteins, the plant virus must be able to independently replicate,
transcribe, and translate. When the virus is replicating, foreign genes are
continually produced, combined with the genes that make the plant virus's
capsid protein, expressed as soluble proteins, and dispersed throughout the
cytoplasm of the host plant cell (Guan et
al. 2013). These plant viruses are manipulated by inserting a gene of
interest. Plant viruses then infect the host, and genes are expressed in
various areas of the plant, however, the amount of expression varies (Maliga
2002). Many viruses, such as the CPMV (Cowpea Mosaic Virus), alfalfa
mosaic virus, TMV (Tobacco Mosaic Virus), CaMV (Cauliflower Mosaic Virus),
potato virus, and tomato bushy stunt virus, may have their surfaces modified to
produce antigenic protein snippets. The use of overcoat and epicoat
Fig. 1: Schematic
representation of stable nuclear transformation process. A gene of interest is
introduced into plant chromosomes via Agrobacterium-mediated transformation,
followed by selection and regeneration. The edible plant tissue is then fed to
the mouse to check the response of the edible vaccine
technologies is part of this strategy
(Ramshaw and Ramsay 2000). The full protein may be produced by plants using
overcoat technology, but just the foreign proteins may be expressed by them
using epicoat technology (Karasev et al.
2005).
Cholera: In the small intestine, enterotoxigenic
Escherichia coli (ETEC) and Vibrio cholera produce enterotoxins
as colonies, which lead to severe watery diarrhea. Cholera toxin (CT) and
heat-labile enterotoxin (LT) from E. coli are both protein toxins with
similar immunochemical characteristics. The GM1 ganglioside on the surface of
intestinal epithelial cells is where LT and CT interact through specific
interactions with the B-subunit pentamer. To provide immunization against CT-B
and avoid damage, a vaccination taken orally comprising CT-B subunits and
testing was done on entirely dead cholera cells in Bangladesh. The host
cells are prevented from receiving a component. Recombinant potato LT-B tubers
were administered to mice in one experiment to induce blood and mucosal
antibodies against LT-B, which had the intended result of providing protection
against oral challenge with LT. The findings demonstrated that plant-expressed
LTB can be administered as an adjuvant or part of an anti-ETEC injection and
anti-cholera vaccines. Given the similarity between CT and LT, CT-B produced in
plants would also provide protection. Another study discovered that the plant
chemical CT-B increased the production of toxin-neutralizing antibodies in mice
(Mason et al. 1998).
Hepatitis B: One of the diseases that concern people
the most in poor countries is hepatitis B, with around 350 million chronic
carriers. The illness can be treated with vaccinations; however, the
recombinant vaccine made from yeast is exceedingly costly in impoverished
countries. It could be more affordable to produce the hepatitis B vaccine in
food plants and fruits. Transgenic plants, including tobacco, carrot, potato,
lettuce, and lupin, have been shown to express the hepatitis B surface antigen
(HBsAg). The capacity to immunize huge populations, infant digestibility and
palatability, year-round availability, absence of transgenic segregation and
ability to produce palatable hepatitis vaccinations make banana a great
candidate. Using techniques like Agrobacterium-mediated transformation,
particle bombardment, or electroporation, banana has successfully undergone
genetic modification, enabling the transfer and expression of advantageous
genes (Kumar et al. 2005). Using transgenic potato tubers, preclinical animal
experiments developed recombinant hepatitis B surface antigens (HBsAg). A main
immunological response was observed in mice given transgenic HBsAg potato
tubers (Richter et al. 2000).
Newcastle Disease: Shariari and his colleagues sought to
produce a recombinant vaccination in hairy roots in 2015. The pBI121 expression
vector was used to clone the epitopes for the haemagglutinin neuraminidase (HN)
and Newcastle disease virus fusion (F). The vector was subsequently introduced
into tobacco leaf discs using Agrobacterium rhizogenic (Nicotiana tabacum L.). PCR was used to validate the heterologous
gene's incorporation into the hairy root genome. To measure gene expression,
dot-blot and ELISA tests, real-time PCR, and ELISA assays at the translational
and transcriptional levels were applied. They all verified that the recombinant
protein was made and that the heterologous gene was expressed (Shahriari et al. 2015).
Measles: Measles causes 800,000 fatalities globally each year,
with the majority of those afflicted developing encephalitis or going deaf.
During the immunization period, those above the age of 18 months produced 95%
seroconversion. A live-attenuated measles vaccination can be damaged by heat,
which does not need oral immunization and just requires refrigeration for
storage. Moreover, maternal antibodies reduce the vaccination response to the
vaccine. Tobacco plants were genetically modified utilizing plasmid/vector A.
tumefactiens to produce the measles virus hemagglutinin (MV-H) antigen for
an edible vaccine (Huang et al. 2001). After oral treatment of a
plant expressing MVH, serum antibodies were generated that were capable of
neutralizing wild-type MV while yet retaining its immunogenicity. As a result,
mice given plant-derived MV-H orally exhibited IgA antibodies in their feces
(Ishiwada et al. 2001). A transgenic
carrot plant that may be used to disseminate the virus' antigens was shown to
be developing a measles vaccine in another investigation (Marquet-Blouin et
al. 2003). In one
experiment, transgenic bananas were administered to healthy animals, and
antibodies were monitored in blood samples directed against hemagglutination.
The study showed that experimental animals exposed to antigenic
hemagglutination proteins generated from banana plants might trigger
immunological responses (Diane et
al. 2002).
Rabies virus vaccine: For a large portion of the world's
population, the rabies virus poses a substantial risk to both human and animal
health. Antigens from the rabies virus glycoprotein (G protein) and
nucleoprotein (N protein) can be used to create vaccines. The N protein
activates T lymphocytes specific to the rabies virus, whereas the G protein is
the primary antigen that triggers protective immunization. Both support other
immunological processes as well as neutralize antibody production. Tobacco and
spinach plants were created using chimeric peptides that were cloned and
synthesized and contained rabies virus glycoprotein and nucleoprotein antigenic
components. As a result, recombinant virus-carrying mice showed resistance to
infection. Infected spinach leaves were ingested by three out of five human
participants, who afterward experienced an allergic response to the peptide
antigen (Yusibov et al. 2002). In both transgenic tomato plants and N.
benthamiana plants, the full-length nucleoprotein gene of the rabies virus
was generated using agroinfiltration. 1–5% of the total soluble protein was
expressed in both tomato and N. benthamiana (Perea et al. 2008). In a different experiment, chimeric proteins
comprising synthetic CT-B attached to rabies surface glycoprotein at their
C-termini were produced in tobacco plants (G protein). About 80.3 kDa fusion
polypeptide was expressed at 0.4% of the total soluble protein in the leaves of
the selected transgenic lines (Roy et al.
2010).
Anti-autoimmune illness vaccinations: To cure
autoimmune illnesses, auto-antigens are generated in transgenic plants. The
immune system perceives bodily proteins as invading substances. Type 1 diabetes,
myasthenia gravis, arthritis and multiple sclerosis are all illnesses. When
administered orally, an autoantigen made from plants will halt the progression
of the autoimmune disease (Langridge 2000).
GAD (Glutamic acid decarboxylase) and insulin-producing potatoes have been
shown to lessen diabetic immunological assaults and the prevention of the
initiation of high blood sugar (Arakawa et
al. 2007).
Vaccines against human tumors: Several tumors,
including melanoma and breast cancer, have specific proteins on their cell
surfaces. Antibodies against these antigens that are passively supplied,
naturally acquired, or actively produced have eradicated circulating tumor
cells and micrometastasis. Since tumor antigens are also auto-antigens,
developing a cancer vaccine becomes more difficult. During the past 10 years,
immunologists have discovered and classified epitopes unique to a variety of human
tumor types. For instance, a polyepitope-containing naked recombinant plasmid
DNA was recovered from a human melanoma tumor. Mice were injected with the
plasmid DNA, which causes a cytotoxic T-cell response that is epitope specific.
With the purpose of developing this DNA, a melanoma vaccine obtained from
plants, is now being integrated into the nuclear and chloroplast DNA of tobacco
(Sala et al. 2003).
As edible plant vaccines may be used as
a dietary supplement and activate the humoral, cell-mediated and mucosal immune
systems, they offer several benefits. Compared to normal methods, transgenic
plants' production costs are much less. When expressed in plants' natural
storage tissues, foreign proteins become more stable and don't need to be
refrigerated, shipped, or stored as much. Plant tissues, components and without
the need for any additional equipment, all extracts can be stored at ambient
temperature. Only a minor portion of a pathogen's antigenic component is
generated in plants, which lowers the danger of infection and contamination
with mammalian viruses because plants are not hosts for animal viruses. The
antigen is shielded by the plant cell walls from digestion and eventually
released into the lymph and blood. Several transgenic lines combined with seeds
can produce multicomponent vaccines that express various proteins (Streatfield et al. 2001; Shahriari et al. 2015). Purification is not
required because the plant includes recombinant proteins in edible form, such
as potatoes. Sexual crossing of plants can introduce new or numerous
transgenes. Transgenic animal ethical issues are avoided (Malik et al. 2011).
Although the concept of edible
vaccination is appealing, its execution may be difficult. While developing a plant-based
vaccine, there are several factors to take into account, such as system
efficacy, dosage, antigen choice, administration, safety, public perception and
quality control, plant choice, and licensing. The antigen of choice needs to
work with the type of plant in which it will be expressed. The patient's
weight, age, size and the fruit or plant's ripeness all have a role in
determining the dosage of an edible vaccine. Under dosing, which would lead to
reduced antibody production, or overdosing, which would lead to tolerance,
might arise from this. It is difficult to maintain dosage constancy from fruit
to fruit, plant to plant, and generation to generation. The shelf life of the
fruits, herbs, and vegetables used as vaccines is crucial. To prevent infection
or sickness from degrading, these vector plants must be kept in good condition.
The ability to distinguish "vaccine" fruit from conventional fruit in
order to reduce improper vaccination delivery may be another concern.
Plant-based vaccines may result in allergic reactions or negative side effects,
such as autoimmune diseases, central nervous system injury, or cytokine-induced
sickness (Sharma and Sood 2011).
Most infections enter the body through
mucous membranes. Parenteral administration of candidate antigens cannot
sufficiently activate the mucosal immune system, in contrast to the humoral
immune system. Oral vaccines are extremely important because they are effective
in stimulating mucosal immunity at the intestine's surface. Edible plant
vaccines provide good protection against a wide range of diseases that come
into touch with the body's mucosal surfaces via the oral, respiratory, urinary
and vaginal pathways. They may be used independently or in combination with
other vaccination techniques. Since antigens must be presented directly to the
mucosal surface, oral vaccinations are the best technique to develop mucosal
immunity. Subunit vaccines have yet to achieve economic value through any
method of manufacture. The primary issue with using orally given immunogenic
proteins is that they degrade after ingestion and may not be recognized
efficiently in the stomach. Plant cell walls protect vaccinations and can
overcome degradation problems, such as liposomes and microcapsules. The thick
surface of the lower digestive tract is covered by a large amount of plant cell
wall, allowing for a delayed release of the antigen (Streatfield et al. 2001; Habibi-Pirkoohi and Mohkami
2015).
Mucosal surfaces, encompassing the
respiratory, digestive, urinary, and reproductive systems, occupy most of the
body's immunologically active tissue. The mucosal immune system (MIS) is the
first line of defense against viruses that specifically target mucosal surfaces
and is the best place for immunization. An edible vaccine seeks to promote
humoral and mucosal defenses against diseases. During oral delivery, edible
vaccines are chewed up, and the majority of plant cell death is caused by
digestive or bacterial enzyme action on edible vaccines in the colon. In
transgenic plants, antigens are transported by bio-encapsulation. Plant cells
have a tough outer coating that shields them from stomach acids and eventually
disintegrate in the intestines. M-cells that are positioned on top of Peyer's
patches take up the antigens once they are released in the colon. Peyer's
Patches (PP)-derived IgA-producing plasma cells have the potential to enter
mucosal tissue and act as mucosal immune effector sites. They consist of 30 to
40 lymphoid nodules on the outside of the digestive tract, each of which has
follicles from which germinal centers form in response to the antigenic
stimulation caused by the breakdown of ingested vaccines. The antigen enters
the intestinal epithelium through these follicles and gathers inside
specialized lymphoid tissues. As a result of interaction, the antigen is
subsequently carried by M-cells, which express class II MHC molecules beyond
the mucosal barrier and activates B cells in lymphoid follicles. When it
interacts with the lumen, a group of B-cells, T-cells and macrophages produces
a profound invagination in the basolateral plasma membrane. In the
mucosal-associated lymphoid tissue (MALT), activated B-cells travel from
lymphoid follicles and mature into plasma cells that produce IgA antibodies.
Epithelial cells transport IgA antibodies into lumen secretions where they
interact with antigens found there (Table 1; Fig. 2). The memory cells and IgA
response would quickly stop the actual infectious agent's invasion (Mishra et
al. 2008; Esmael and Hirpa 2015).
Foreign antigens factory-made in plants: Before the development of edible
vaccines, several concerns had been expressed about the use of injectable
vaccines, which have been the standard form of immunization since 1995. Arntzen
and his associates engineered a tobacco plant that could synthesize a protein
from the hepatitis B virus by introducing the gene for that protein into the
plant. This is just one example of how many foreign genes were generated in
diverse plants in the proper conformation. The immune system components of the
mice were then activated similarly to how a virus could by administering this
antigen via injection.
Plant-based diabetes vaccinations: Langridge created plant-based
diabetes vaccines, such as potatoes infused with insulin or GAD linked to the
harmless B fractional monetary unit of the deadly toxin V. cholerae (to increase the antigens' absorption by M cells). The
immunizations were given to a strain of mice that developed diabetes as a
result of the vaccinations. This assisted in limiting the immunological
response and delaying the onset of high blood pressure (Langridge 2000).
Mouse LT-B antibody production in serum and mucosa: Numerous
researches for vaccine development in plants were conducted, and it was also
shown that mice may create serum and mucosal antibodies against LT-B. These
antibodies were generated by feeding mice transgenic potato tubers with an
altered LT-B at a level of 2 pg gg' tuber tissue. The principal source of LT
inhibition in mammalian cells was therefore considered to be antibodies
produced in response to potato LTB. They were effective in protecting as a
result. In order to boost LT-B production in potato plants, a fake LT-B (sLT-B)
encryption sequence that has been altered to include plant-preferred codons and
reduce erroneous mRNA process signals was utilized. When administered to mice,
the sLT-B tubers produced significant blood and mucosal antibody responses
against LT-B and provided some protection against an oral LT-B challenge (Mason et
al. 1998). LT B was also expressed in corn by S.J Streatfield and
also its immunogenicity was described when fed to mice.
Immune response aggravated by transgenic potatoes: When HBsAg was
expressed in transgenic tomato leaves; VLPs with a diameter of 22nm were
produced. Afterward, it was employed in mice for duct creation, and VLPs
induced a B and T cell immune response, which is equal to yeast derive
vaccination (Richter et al. 2000).
Human Trials
In the first human experiment of an
edible plant vaccine designed to boost active immunity, 14 adult volunteers
were randomly assigned to receive either 100 g of transgenic potatoes, 50 g of
transgenic potatoes, or 50 g of wild-type potatoes (Tacket et al. 1998). According
to the promoter's tissue specificity, there were different amounts of LT-B per
gram of potato, which may indicate that LT-B was expressed Table 1: Edible vaccines produced in
transgenic plants
Disease |
Antigen |
Plant Host |
Effect of vaccine |
Reference |
Cholera |
E. coli heat labile
enterotoxin (LT-B) |
Potato |
Protection against LT-B in mice was
induced |
(Mason et al. 1998) |
Newcastle |
Fusion (F) and haemagglutinin
neuraminidase (HN) epitopes |
Tobacco |
The
expression of the heterologous gene and production of the recombinant protein
was confirmed by PCR, dot-blot and ELISA assays. |
(Shahriari et al. 2015) |
Measles |
Measles virus hemagglutinin (MVH)
antigen |
Tobacco |
The serum antibodies were induced
which were able to neutralize wild type MV. The animals immunized with MV-H
had IgA antibodies in the fecal samples. |
(Ishiwada et al. 2001) |
Rabies |
A chimeric peptide comprising
antigenic determinants from glycoprotein and nucleoprotein of rabies virus |
Spinach |
The mice
showed immunity against challenge infection |
(Yusibov et al. 2002) |
Rabies |
A full-length nucleoprotein gene of
the rabies virus |
Tomato and N. benthamiana |
1–5 % of
total soluble protein was expressed in tomato and 45% in N. benthamiana |
(Perea et al. 2008) |
Hepatitis B |
A recombinant hepatitis B surface
antigen (HBsAg) |
Potato |
Mice fed
transgenic HBsAg potato tubers showed a primary immune response |
(Richter et al. 2000) |
Fig. 2: Representation
of immunological mechanisms of action of plant-based edible vaccines
in different
potato tissues to varying degrees. Whereas the potatoes were ingested raw in
this study, following research has demonstrated that only about 50% of the CTB
pentameric GM1-binding form may be lost by cooking transgenic potatoes encoding
the cholera toxin B component for 3 min until the tissue softens (Wang et al. 2004). Serologic reactions also
appeared after immunization. When transgenic potatoes were ingested by 11
participants, 10 (91%) of them developed IgG anti-LT antibodies, with half of
them responding after the first dosage. In six (55%) of the 11 patients, serum
IgA anti-LT levels multiplied (Tacket et
al. 1998). The National Institute of Allergy and Infectious Diseases claims that
transgenic plant immunization can effectively stimulate people's immune systems
(NIAID). Little, raw potato pieces that had been genetically altered to
generate a tiny quantity of the diarrheal toxin produced by E. coli were
given to participants (Ball et al. 1999). Transgenic potatoes
producing this toxin component induced potent immunological responses in mice,
according to in vitro and preclinical research previously funded by NIAID. The
creation and development of transgenic potatoes use scientific methods. The genetically
modified potatoes were given to 11 of 14 healthy individuals at random, while
the remaining three received conventional potatoes. The potential of the
vaccination to trigger intestinal and systemic immune responses was assessed
using routine blood and stool samples from patients. After vaccination, six out
of the eleven volunteers (55%) experienced a fourfold rise in intestine
antibodies, and ten out of the eleven (91%) experienced a fourfold increase in
blood antibodies at some time after consuming the transgenic potatoes. The
participants tolerated the potatoes well and none of them reported any serious
side effects. The NIAID-supported researchers were inspired to look into using
this method to deliver other antigens by the study's encouraging results. To
combat the Norwalk virus, diarrhea, and hepatitis B, potatoes, tomatoes and
bananas are being grown. Research is also being done on edible vaccines for
other intestinal illnesses (Pyrski et al. 2019).
Being able to fold and assemble
proteins correctly, plants and fruits are increasingly used as expression sites
for the development of ingestible vaccines. Transgenic plant vaccines provide a
number of advantages over conventional vaccinations, including safety,
cost-effectiveness, consistency, and competence. Orally given edible plant
vaccinations can stop the spread of illness. Transgenic plant vaccines will,
however, take a long time to produce in large quantities and become
commercially available. Yet, a lot of vaccination research is still in the
testing phase. The marketing of a transgenic plant vaccine that prevented
Newcastle disease was authorized by the United States Department of Agriculture
(USDA) in 2006. This illustration will encourage the development and
manufacture of further transgenic plant vaccines. Plants may overtake other
molecular agricultural production methods in the near future because to their
benefits in terms of safety and economics. It follows that the application of
inexpensive edible vaccinations against a variety of illnesses is anticipated
in the future.
Acknowledgment
The Department of Bioinformatics and
Biotechnology at the International Islamic University in Islamabad is
gratefully acknowledged by the authors for providing a conducive research
environment.
Author Contributions
All authors contributed equally.
Conflict of Interest
All authors declare no conflict of
interest.
Data Availability
All of the data is available within
this review article.
Ethics Approval
Funding Source
This review received
no specific grant from any funding agency in the public, commercial, or
not-for-profit sectors.
Arakawa T, J Yu, DK Chong, J Hough, PC Engen, WH Langridge (2007). A
plant-based cholera toxin B subunit-insulin fusion protein protects against the
development of autoimmune diabetes. Nat Biotechnol
16:934‒938
Ball JM, DY Graham, AR Opekun, MA Gilger, RA Guerrero, MK Estes (1999).
Recombinant Norwalk virus–like particles given orally to volunteers: phase I
study. Gastroenterology 117:40‒48
Chan HT, H Daniell (2015). Plant-made oral vaccines against human
infectious diseases – Are we there yet? Plant Biotechnol J 13:1056‒1070
Cortina C, FA Culiáñez-Macià (2004). Tomato transformation and
transgenic plant production. Plant Cell Tiss
Org Cult 76:269‒275
Diane EW, MC Thomas, RA Strugnell, IB Dry, SL Wesselingh (2002).
Appetizing solutions: An edible vaccine for measles, Med J Aust 176:434‒437
Dorokhov YL, AA Sheveleva, OY Frolova, TV Komarova, AS Zvereva, PA
Ivanov, JG Atabekov (2007). Superexpression of tuberculosis antigens in plant
leaves. Tuberculosis 87:218‒224
Doshi V, H Rawal, S Mukherjee (2013). Edible vaccines from GM crops:
current status and future scope. J Pharm
Sci Innov 2:1‒6
Esmael H, E Hirpa (2015). Review on Edible Vaccine. Acad J Nutr 4:40–49
Famulare M, H Hu (2015). Extracting transmission networks from
phylogeographic data for epidemic and endemic diseases: Ebola virus in Sierra
Leone, 2009 H1N1 pandemic influenza and polio in Nigeria. Intl Health 7:130‒138
Guan ZJ, B Guo, YL Huo, ZP Guan, JK Dai, YH Wei (2013). Recent advances
and safety issues of transgenic plant-derived vaccines. Appl Microbiol Biotechnol
97:2817‒2840
Habibi-Pirkoohi M, A Mohkami (2015). Recombinant vaccine production in
green plants: State of art. J Cell Mol Res 7:59‒67
Haq TA, HS Mason, JD Clements, CJ Arntzen (1995). Oral immunization
with a recombinant bacterial antigen produced in transgenic plants. Science 268:714‒716
Hefferon K (2013). Plantderived pharmaceuticals for the
developing world. Biotechnol J 8:1193‒1202
Huang Z, I Dry, D Webster (2001). Plant derived measles virus
hemagglutinin protein induces neutralizing antibodies in mice. Vaccine 19:2163‒2171
Ishiwada N, MM Addae, JK Tetteh (2001). Vaccine modified measles in
previously immunized children in Accra, Ghana: clinical, virological and
serological parameters. Trop Med Intl
Health 6:694‒698
Karaman S, J Cunnick, K Wang (2006). Analysis of immune response in
young and aged mice vaccinated with corn-derived antigen against Escherichia
coli heat-labile enterotoxin. Mol
Biotechnol 32:31‒42
Karasev AV, S Foulke, C Wellens, A Rich, KJ Shon, I Zwierzynski, D
Hone, H Koprowski, M Reitz (2005). Plant-based HIV-1 vaccine candidate: Tat
protein produced in spinach. Vaccine 23:1875–1880
Kim YS, MY Kim, TG Kim, MS Yang (2009). Expression and assembly of
cholera toxic B subunit (CTB) in transgenic carrot (Daucus carota L.). Mol
Biotechnol 41:8–14
Kumar GS, TR Ganapathi, CJ Revathi, L Srinivas, VA Bapat (2005).
Expression of hepatitis B surface antigen in transgenic banana plants. Planta
222:484‒493
Langridge WH (2000). Edible vaccines. Sci Amer 283:66–71
Li HY, S Ramalingam, ML Chye (2006). Accumulation of recombinant
SARS-CoV spike protein in plant cytosol and chloroplasts indicate potential for
development of plant derived oral vaccines. Exp
Biol Med 231:1346‒1352
Lou XM, Z Zhang, HQ Yao, AS Xiong, HK Wang, RH Peng, X Li (2005).
Expression of human hepatitis B virus large surface antigen gene PRS-S1S2S in
transgenic apples. J Fruit Sci 22:601‒605
Maliga P (2002). Engineering the plastid genome of higher plants. Curr Opin Plant Biol 5:164‒172
Maliga P (2001). Plastid engineering bears fruit. Nat Biotechnol 19:826‒827
Malik A, VK Vashishta, R Rizwan, S Sharma, J Singh (2011). Edible
vaccine-vegetables as alternative to needles. Intl J Curr Res 3:18‒26
Marquet-Blouin E, FB Bouche, A Steinmetz, CP Muller (2003).
Neutralizing immunogenicity of transgenic carrot (Daucus Carota L.) derived measles virus hemagglutinin. Plant Mol Biol 51:458‒469
Mason HS, H Warzecha, T Mor, CJ Arntzen (2002). Edible plant vaccines:
applications for prophylactic and therapeutic molecular medicine. Trends Mol
Med 8:324‒329
Mason HS, TA Haq, JD Clements, CJ Arntzen (1998). Edible vaccine
protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes
expressing a synthetic LT-B gene. Vaccine 16:1336‒1343
Mishra N, PN Gupta, K Khatri, AK Goyal, SP Vyas (2008). Edible vaccines:
A new approach to oral immunization. Ind J Biotechnol 7:283‒294
Perea AI, EL Rubio, ER Anaya, TO Flores, LGDL Vara, MA Gómez Lim
(2008). Expression of the rabies virus nucleoprotein in plants at high-levels
and evaluation of immune responses in mice. Plant
Cell Rep 27:677‒685
Pyrski M, AA Mieloch, A Plewiński, A Basińska-Barczak, A
Gryciuk, P Bociąg, M Murias, JD Rybka, T Pniewski (2019). Parenteral–oral
immunization with plant-derived HBcAg as a potential therapeutic vaccine
against chronic hepatitis B. Vaccines 7:211–220
Ramshaw IA, AJ Ramsay (2000). The prime-boost strategy: exciting
prospects for improved vaccination. Immunol
Today 21:163‒165
Richter LJ, Y Thanavala, CJ Arntzen, HS Mason (2000). Production of
hepatitis B surface antigen in transgenic plants for oral immunization. Nat Biotechnol 18:1167‒1171
Rossi L, S Reggi, M Zaninelli, F Saccone, D Gottardo, A Crotti, A Baldi
(2015). Evaluation of antigens stability of tobacco seeds as edible vaccine
against VTEC strains. Intl J Health Anim Sci Food Saf 2:2283‒3927
Roy S, A Tyagi, S Tiwari, A Singh, SV Sawant, PK Singh, R Tuli (2010)
Rabies glycoprotein fused with B subunit of cholera toxin expressed in tobacco
plants folds into biologically active pentameric protein. Protein Exp Purif 70:184‒190
Sala F, MM Rigano, A Barbante, B Basso, AM Walmsley, S Castiglione
(2003). Vaccine antigen production in transgenic plants: strategies, gene
constructs and perspectives. Vaccine 21:803‒808
Singh B (2002). Biotechnology,
Vol. 1, p:323. Kalyani publishers, New Delhi, India
Shahriari AG, A Bagheri, MR Bassami, SM Shafaroudi, AR Afsharifar
(2015). Cloning and expression of Fusion (F) and Haemagglutinin-neuraminidase
(HN) Epitopes in hairy roots of tobacco (Nicotiana
tabacum L.) as a step toward developing a candidate recombinant vaccine
against newcastle disease. J Cell Mol Res 7:11‒18
Sharma M, B Sood (2011). A banana or a syringe: journey to edible
vaccines. World J Microbiol Biotechnol 27:471‒477
Stander J, S Mbewana, AE Meyers (2022). Plant-derived human vaccines:
Recent developments. Biol Drugs 36:573‒589
Streatfield SJ, JM Jilka, EE Hood, DD Turner, MR Bailey, JM Mayor, IR
Tizard (2001). Plant based vaccines: unique advantages. Vaccine 19:2742‒2748
Tacket CO, HS Mason (1999). A review of oral vaccination with
transgenic vegetables. Microb Infect 1:777‒783
Tacket CO, HS Maso, G Losonsky, JD Clements, MM Levine, CJ Arntzen
(1998). Immunogenicity in humans of a recombinant bacterial antigen delivered
in a transgenic potato. Nat Med 4:607‒609
Tregoning J, P Maliga, G Dougan, PJ Nixon (2004). New advances in the
production of edible plant vaccines: chloroplast expression of a tetanus
vaccine antigen, Tet C. Phytochemistry
65:989‒994
Walmsley AM, CJ Arntzen (2000). Plants for delivery of edible vaccines.
Curr Opin Biotechnol 11:126‒129
Wang L, MW Goschnick, RL Coppel (2004). Oral immunization with a
combination of Plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances
protection against lethal malaria challenge. Infect Immun 72:6172‒6175
Wang YQ, T Li (2008). Transformation of HBsAg gene into tomato and
production of transgenic tomato plants. JSW
Univ (Nat Sci Edn) 30:78‒83
Yusibov V, DC Hooper, SV Spitsin, N Fleysh, RB Kean, T Mikheeva, D
Deka, A Karasev, S Cox, J Randall, H Koprowski (2002). Expression in plants and
immunogenicity of plant virus-based experimental rabies vaccine. Vaccine 20:3155‒3164